AMRNClinical Trials•globenewswire•
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
Sentiment:Negative (30)
Summary
(NASDAQ:AMRN) -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- -- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action --
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 31, 2025 by globenewswire